GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alkermes PLC (NAS:ALKS) » Definitions » Total Current Liabilities

Alkermes (Alkermes) Total Current Liabilities : $520 Mil (As of Dec. 2023)


View and export this data going back to 1991. Start your Free Trial

What is Alkermes Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Alkermes's total current liabilities for the quarter that ended in Dec. 2023 was $520

Alkermes Total Current Liabilities Historical Data

The historical data trend for Alkermes's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alkermes Total Current Liabilities Chart

Alkermes Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 391.11 438.26 471.29 497.74 520.22

Alkermes Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 497.74 492.91 487.19 503.11 520.22

Alkermes Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Alkermes's Total Current Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=421.095+8.746
+Other Current Liabilities+Current Deferred Liabilities
=87.649+2.73
=520

Alkermes's Total Current Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=421.095+8.746
+Other Current Liabilities+Current Deferred Liabilities
=87.649+2.73
=520

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Alkermes Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Alkermes's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Alkermes (Alkermes) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alkermes PLC (NAS:ALKS) » Definitions » Total Current Liabilities
Comparable Companies
PRGO LNTH PBH ALVO ITCI AMPH SUPN TLRY AMRX DVAX ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA TSE:4507 VTRS NBIX XSWX:SDZ
Traded in Other Exchanges
8AK:Germany
Address
1 Burlington Road, Connaught House, Dublin, IRL, D04 C5Y6
Website
https://www.alkermes.com
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies.
Executives
Cato T Laurencin director C/O UNIVERSITY OF CONNECTICUT, 263 FARMINGTON AVENUE, FARMINGTON CT 06030-3800
Christian Todd Nichols officer: SVP, Chief Commercial Officer 852 WINTER STREET, WALTHAM MA 02451
Nancy Wysenski director 2200 SUNBURST STREET, CHATSWORTH CA 90401
Daglio David Angelo Jr. director ALKERMES, 852 WINTER STREET, WALTHAM MA 02451
Christopher I Wright director C/O CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE MA 02142
Michael J Landine officer: SVP, Corp Dev., Alkermes, Inc. 88 SIDNEY ST, CAMBRIDGE MA 021394136
Richard F Pops director, officer: Director and CEO, Alkermes plc 10555 SCIENCE CENTER DR, SAN DIEGO CA 92121
Shane Cooke officer: President, Alkermes plc TREASURY BUILDING LOWER GRAND CANAL ST., DUBLIN 2 L2 00000
Blair Curtis Jackson officer: EVP, Chief Operating Officer 852 WINTER STREET, WALTHAM MA 02451
Snyderman Nancy Lynn Md director 37 PHEASANT HILL ROAD, PRINCETON NJ 08540
Craig C. Hopkinson officer: SVP, Med Dev/Med Affairs, CMO 852 WINTER STREET, WALTHAM MA 02451
Emily Peterson Alva director C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Iain Michael Brown officer: VP, Finance & CAO 14 ROYALSTON AVENUE, WINCHESTER MA 01890
Brian P Mckeon director IDEXX LABORATORIES, ONE IDEXX DRIVE, WESTBROOK ME 04092
David Joseph Gaffin officer: SVP, CLO, Alkermes, Inc. 852 WINTER STREET, WALTHAM MA 02451